Trials / Completed
CompletedNCT05370950
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
A Single-center, Randomized, Parallel, Open-label Study to Compare the Bioavailability, Pharmacodynamics, and Safety of SHR-1209 Given as Single Subcutaneous Injection at Different Sites in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety data to assess feasibility of multiple injection sites for administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1209 | SHR-1209，single subcutaneous injection of 450mg |
Timeline
- Start date
- 2022-05-25
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2022-05-12
- Last updated
- 2023-01-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05370950. Inclusion in this directory is not an endorsement.